Or Sell — Merck Stock Buy

As of April 2026, the analyst consensus for is a Buy . While near-term performance may be impacted by generic competition and clinical setbacks, the majority of analysts maintain a bullish outlook based on the strength of its oncology portfolio and active acquisition strategy. Analyst Sentiment and Price Targets